Okta, Inc.

**Signal Note: Eventide Initiates OKTA Position** Eventide's $342K entry into Okta appears misaligned with its biotech-focused mandate, suggesting either portfolio diversification into cybersecurity infrastructure or a defensive positioning around identity/access management—a non-drug asset. This signals no direct biotech catalyst and warrants clarification on strategic rationale, as it deviates from the fund's core thesis.